Metformin Brain Pathway: New Research After 60 Years
- Researchers at Baylor College of Medicine and international collaborators have identified a crucial brain pathway involved in the anti-diabetic effects of metformin, a drug used for over 60...
- For decades, metformin has been a cornerstone in the treatment of type 2 diabetes.
- "It's been widely accepted that metformin lowers blood glucose primarily by reducing glucose output in the liver.
“`html
Metformin‘s Brain Connection: New insights into Diabetes Treatment
Table of Contents
Researchers at Baylor College of Medicine and international collaborators have identified a crucial brain pathway involved in the anti-diabetic effects of metformin, a drug used for over 60 years to manage type 2 diabetes. The discovery, published in Science Advances on September 6, 2024, opens new avenues for more effective and targeted diabetes therapies.
Last updated: September 10, 2025, 11:33:01 AM PDT
the Long-Standing Mystery of Metformin
For decades, metformin has been a cornerstone in the treatment of type 2 diabetes. Though, despite its widespread use, the complete mechanism of action remained elusive. Customary understanding focused on the liver and gut, but a thorough picture was missing. Recent research suggests a more complex interplay of factors influencing metformin’s efficacy.
“It’s been widely accepted that metformin lowers blood glucose primarily by reducing glucose output in the liver. Other studies have found that it acts through the gut,” explained Dr. Makoto Fukuda, associate professor of pediatrics – nutrition at Baylor College of Medicine and corresponding author of the study. “We looked into the brain as it is widely recognized as a key regulator of whole-body glucose metabolism. We investigated whether and how the brain contributes to the anti-diabetic effects of metformin.”
Uncovering the Brain’s Role: Rap1 and the Ventromedial Hypothalamus
The research team zeroed in on a small protein called Rap1, located within the ventromedial hypothalamus (VMH), a specific region of the brain. Their findings revealed that metformin’s ability to lower blood sugar, at doses commonly used in clinical practice, is dependent on the suppression of Rap1 activity in the VMH.
Specifically, the study demonstrated that metformin effectively reduces blood glucose levels by inhibiting Rap1 in the VMH. This inhibition, in turn, influences downstream signaling pathways that regulate glucose metabolism. The researchers used a combination of genetic and pharmacological approaches to demonstrate this causal link.
Implications for Diabetes Treatment
This discovery has meaningful implications for the future of diabetes treatment. By identifying a brain pathway involved in metformin’s action, researchers have opened up new possibilities for developing more targeted and effective therapies. Understanding how metformin interacts with the brain could lead to the design of drugs that specifically modulate Rap1 activity or other related pathways.
“This is a paradigm shift in how we think about metformin,” Dr. Fukuda stated. “It suggests that targeting the brain could be a viable strategy for improving glucose control in patients with type 2 diabetes.”